Brooklyn College Cancer Center Funding Opportunities Directory

Funding
Opportunities
Directory

Search:


BCCC-CURE/ACS Pilot Grants	2026-03-31	$40,000	Brooklyn College Cancer Center (BCCC-CURE)	Early Career / Mid-Career	Click for details This one-year grant is open to full-time faculty at Brooklyn College within the first 6-years of initial appointment, or faculty transitioning to Cancer Research from related areas. Application deadline March 31st, 2026, 5:00PM
RFA: American Cancer Society - Flatiron Real-World Data Impact Award	2026-04-01	$100,000	American Cancer Society (ACS)	Early Career / Mid-Career	Click for details The Real-World Data Impact Award (RWIA) supports the American Cancer Society’s and Flatiron’s goals of accelerating cancer research that informs public health, public policy, and ultimately improves clinical practice. This RFA is a call for investigators to propose cancer research questions which utilize Flatiron’s electronic health record (EHR)-derived database from 1000+ unique sites of care. Flatiron extracts and processes both structure and unstructured data from millions of patients’ electronic health records to develop disease-specific longitudinal datasets. This award seeks to advance the use of real-world evidence (RWE) to address clinically relevant questions that are difficult or infeasible to answer through traditional clinical trials alone. Interest applicants are encouraged to review published research that utilized Flatiron data.
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)	2026-04-08	varies to reflect the needs of the project	National Institutes of Health (NIH)	Predoctoral Students	Click for details The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral (Parent F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from appropriate faculty sponsors while conducting biomedical research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must address the candidate’s identified research training and career goals and enhance the candidate's potential to successfully transition to the next phase of their biomedical research career.
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)	2026-04-08	varies to reflect the needs of the project	National Institutes of Health (NIH)	Postdoctoral Students	Click for details The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral (Parent F32) award is to enable promising postdoctoral students to obtain individualized, mentored research training from appropriate faculty sponsors while conducting biomedical research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must address the candidate’s identified research training and career goals and enhance the candidate's potential to successfully transition to the next phase of their biomedical research career.
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)	2026-04-08	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers.
AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship	2026-04-09	$130,000	American Association for Cancer Research (AACR)	Postdoctoral Fellow	Click for details The AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship is a joint effort to support and encourage innovative research projects with direct applicability and relevance to ILC and to help establish a successful career path in the field. This fellowship provides a two-year grant of $130,000 to support the salary and benefits of postdoctoral or clinical research fellows working on mentored ILC research projects. A portion of these funds may be designated for non-personnel expenses such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses.
AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Innovation and Discovery Grants	2026-04-09	$50,000	American Association for Cancer Research (AACR)	Early Career / Mid-Career	Click for details These grants are intended to support innovative research projects focused on invasive lobular carcinoma (ILC). Applications addressing any aspect of basic or clinical research directly related to lobular breast cancer are eligible. Proposals investigating rare ILC subtypes-such as pleomorphic and alveolar ILC-as well as studies on dormancy and recurrence will receive priority consideration. Each grant provides $50,000 over one year for expenses related to the research project. Grant funds may be used for direct research expenses attributable to the project, which may include supplemental salary support, equipment, research/laboratory supplies, and other research expenses. Up to 5% of grant funds may be used on indirect costs.
AHRQ Conference Grant Programs (R13)	2026-04-12	$50,000/yr up to 3 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The Agency for Healthcare Research and Quality (AHRQ) announces its interest in supporting conferences through the AHRQ Single-Year and Multiple-Year Conference grant programs (R13). AHRQ seeks to support conferences that help further its mission to produce evidence to make health care safer, higher quality, more accessible, equitable and affordable, and to work with HHS and other partners to make sure the evidence is understood and used.
Environmental Health Sciences Core Centers Program (P30 Clinical Trials Optional)	2026-04-20	$850,000/yr up to 4 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details This Notice of Funding Opportunity (NOFO) invites grant applications for Environmental Health Sciences Core Centers (EHSCC). As intellectual hubs for environmental health science research, the EHSCC are expected to be the thought leaders for the field and advance the goals of the 2025-2029 NIEHS Strategic Plan. The Core Centers provide critical research infrastructure, shared facilities, services and/or resources, to groups of investigators conducting environmental health sciences research. An EHSCC enables researchers to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively. The overall goal of an EHSCC is to identify and capitalize on emerging issues that advance improving the understanding of the relationships among environmental exposures, human biology, and disease. The EHSCC supports community engagement and translational research as key approaches to improving public health.
2026 Healthy After Cancer: Childhood Cancer Survivorship Research Award	2026-04-24	$125,000/yr for 2 years	Children’s Cancer Research Fund	Early Career / Mid-Career	Click for details This award is intended to shape the future of cancer survivorship treatment and care. We invite applications that focus on improving the quality and quantity of life for childhood, adolescent, and young adult cancer survivors. Our goal is to support development of interventions that prevent, minimize, and address the late effects of cancer therapies. Proposals to develop drugs or modalities meant to mitigate late effects, as the sole or primary focus, are eligible. Proposals to develop therapeutic approaches (new drugs, modalities, or regimens for treating cancer) are not eligible to apply. In addition, projects that propose to translate basic research into interventions, regardless of whether these take place during active therapy or later, are encouraged. Observational studies are welcome but are a lower priority, except those describing late effects (or early signs of late effects) among children receiving novel agents or therapies.
2026 Eliminating Disparities in Childhood Cancers Award	2026-04-24	$125,000/yr for 2 years	Children’s Cancer Research Fund	Early Career / Mid-Career	Click for details With this award, CCRF wishes to support research that reduces health disparities or inequities in childhood cancer incidence, presentation, access to care, outcome of therapy including adverse event rates, or survivorship. Health disparities are defined here as “systemic, plausibly avoidable health differences adversely affecting socially disadvantaged groups.” (Braveman et al. 2011). CCRF will consider disparities based on race/ethnicity, sex or gender, socioeconomic status, language, geography, or other social determinants of health, so long as their evaluation is supported by the literature. Proposals that identify modifiable risk factors, elaborate mechanisms of disparities or inequities, or which plausibly propose to reduce them, will have greater priority for funding than proposals that simply describe them
AHRQ Health Services Research Dissertation Program (R36)	2026-05-01	varies to reflect the needs of the project	National Institutes of Health (NIH)	Individual at the dissertation stage	Click for details This announcement represents the continuation of an AHRQ program that provides support to individuals who are conducting research undertaken as part of an accredited academic program to qualify for a research doctorate degree.
Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)	2026-05-04	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details Through this Notice of Funding Opportunity (NOFO) entitled "Innovative Research in Cancer Nanotechnology (IRCN)", the National Cancer Institute (NCI) encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address overcoming major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies are expected to be relevant to the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices and sensors in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions. The clinical translation of these interventions is outside of scope of this NOFO.
Foundations for Digital Twins as Catalyzers of Biomedical Technological Innovation	2026-05-04	varies to reflect the needs of the project	National Science Foundation (NSF)	Early Career / Mid-Career	Click for details The Foundations for Digital Twins as Catalyzers of Biomedical Technological Innovation (FDT-BioTech) program supports inherently interdisciplinary research projects that underpin the mathematical and engineering foundations behind the development and use of digital twins and synthetic data in biomedical and healthcare applications, with a particular focus on digital, in silico models used in the evaluation of medical devices and the relevance of the developed models in addressing current and emerging challenges affecting the development and assessment of biomedical technologies. The goal of the FDT-BioTech initiative is to catalyze biomedical technological innovation through new foundational development of methods and algorithms relevant to digital twins and synthetic humans.
Pew Biomedical Scholars	2026-05-13	$75,000/yr for 4 years	The Pew Charitable Trusts	Early Career	Click for details The Pew Scholars Program in the Biomedical Sciences provides funding to young investigators of outstanding promise in science relevant to the advancement of human health.
Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)	2026-05-18	$475,000/yr for 4 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details This Notice of Funding Opportunity (NOFO), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is designed to enable the translation of nanotechnology-based cancer interventions relying on nanoparticle formulations and/or nano-devices. Through the TTNCI initiative, the National Cancer Institute (NCI) encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are expected to mature experimental nanomedicines designed for highly relevant cancer clinical objectives with a strong potential to improve cancer treatment effectiveness. It is expected that improvement of treatment effectiveness will occur due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.
National Science Foundation Translation to Practice (NSF TTP)	2026-05-19	$1,200,000 - $2,000,000/yr up to 4 years	National Science Foundation (NSF)	Early Career / Mid-Career	Click for details The NSF Translation to Practice (NSF TTP) program focuses on real-world applications of all areas of Science, Technology , Engineering, and Mathematics (STEM). Proposers can tailor their research and/or innovation activities to solve specific problems faced by consumers, industries, and/or governments. Successful outcomes of NSF TTP projects are varied and may include, but are not limited to: accelerated product, process or service maturation; open-source projects; standards setting; patents; the realization of pre-commercial or commercial products, processes or services; and startup or small business formation.
Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent T35)	2026-05-25	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grants (T35) to eligible, domestic institutions to develop and/or enhance research training opportunities for predoctoral students interested in careers within biomedical, behavioral, or clinical research workforce. Many NIH Institutes and Centers (ICs) use this NRSA program exclusively to support intensive, short-term research training experiences for health professional students (medical students, veterinary students, and/or students in other health-professional programs) during the summer. This program is also intended to encourage training of graduate students in the physical or quantitative sciences to pursue interests in careers within the biomedical research workforce by providing short-term exposure to, and involvement in, the health-related sciences. The training should be of sufficient depth to enable the trainees, upon completion of the program, to have a thorough exposure to the principles underlying the conduct of biomedical research.
Cancer Research Education Grants Program-Courses for Skills Development (R25 Clinical Trial Not Allowed)	2026-05-25	$300,000/yr for 5 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: courses for skills development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)	2026-05-25	$1,400,000/year for 5 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). Based on the research proposed, applications may be jointly funded with the National Institute of Dental and Craniofacial Research (NIDCR). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this NOFO, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.
Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)	2026-05-25	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to develop and/or enhance predoctoral and postdoctoral research training, including short-term research training, to help ensure that a highly trained workforce is available to meet the needs of the Nation’s biomedical, behavioral, and clinical research agenda. Research training programs are expected to incorporate engaging, didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. Programs proposing only short-term predoctoral research training should not apply to this announcement, but rather to the Kirschstein-NRSA Short-Term Institutional Research Training Grant Program (T35) exclusively reserved for predoctoral, short-term research training.
National Institute of General Medical Sciences Predoctoral Basic Biomedical Sciences Research Training Program (T32)	2026-05-25	varies to reflect the needs of the project	National Institutes of Health (NIH)	Mid-Career	Click for details The goal of the National Institute of General Medical Sciences (NIGMS) Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Basic Biomedical Sciences Research Training Program is to develop a pool of well-trained scientists available to address the nation’s biomedical research agenda. Specifically, this funding announcement provides support to eligible, domestic organizations to develop and implement effective, evidence-informed approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the nation.
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)	2026-05-27	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this notice of funding opportunity (NOFO) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Support for Research Excellence – First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)	2026-05-27	$175,000/yr for 4 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The SuRE program supports research capacity building at eligible higher education institutions through funding investigator-initiated biomedical research in basic, social, clinical, behavioral, or translational science that falls in the mission areas of the NIH. The purpose of SuRE-First awards is to provide support for investigator-initiated research at resource-limited institutions by full-time faculty who have not had any prior independent, peer-reviewed, external research grants, to furnish students with high-quality undergraduate and/or graduate research experiences, and to enhance the institutional scientific research culture.
Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional)	2026-05-27	$1,000,000/yr up to 4 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details This Funding Opportunity Announcement (FOA) is designed to support highly integrated research teams of three to six Program Directors/Principal Investigators (PDs/PIs) to address ambitious and challenging research questions that are within the mission of NIGMS. Project goals should not be achievable with a collection of individual efforts or projects. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields. This FOA is not intended for applications that are mainly focused on the creation, expansion, and/or maintenance of community resources, creation of new technologies, or infrastructure development.
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Human Required)	2026-05-27	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Notice of Funding Opportunity (NOFO) must not include preliminary data. Applications must include a separate attachment describing the change in research direction.The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)	2026-05-27	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details This Funding Opportunity Announcement (FOA) solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies. The goal of the program is to support technological innovations that deliver new capabilities which can realize meaningful solutions within 5 – 10 years.
Building Interdisciplinary Research Careers in Women's Health (BIRCWH) (K12 Clinical Trial Optional)	2026-05-28	$840,000/yr up to 4 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The NIH Office of Research on Women's Health (ORWH) and participating NIH Institutes, Centers, and Offices (ICOs) invite institutional career development award applications for Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Career Development Programs, hereafter termed "Programs". Programs will support mentored research career development of junior faculty members, known as BIRCWH Scholars, who have recently completed clinical training or postdoctoral fellowships, and who will be engaged in interdisciplinary basic, translational, data science, behavioral, clinical, and/or health services research relevant to the health of women and, where appropriate, the use of both sexes to better understand the influence of sex as a biological variable on health and disease. This Notice of Funding Opportunity (NOFO) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.
Research Scholar Grants	2026-06-01	$215,000/yr up to 4 years	American Cancer Society (ACS)	Early Career	Click for details Research Scholar Grants (RSG) provide support for independent, self-directed researchers. Applicants' institutions must provide space and other resources customary for independent investigators. Grant proposals are investigator-initiated and may pursue questions across the cancer research continuum, as long as they fit within an American Cancer Society (ACS) priority research area. These grants typically contribute to the cost of salaries, consumable supplies, and other miscellaneous items required in the research.
Postdoctoral Fellowships	2026-06-01	$66,000 - $70,000/yr for 3 years	American Cancer Society (ACS)	Postdoctoral Fellow	Click for details Postdoctoral Fellowships (PF) support new investigators in research training programs to position them for independent careers in cancer research. As part of their evaluation, peer reviewers consider how well the fellowship will broaden the applicant’s research training and experience.
Clinician Scientist Development Grant (CSDG)	2026-06-01	$135,000/yr up to 5 years	American Cancer Society (ACS)	Early Career / Mid-Career	Click for details The Clinician Scientist Development Grant (CSDG) supports full-time faculty members in becoming independent investigators as clinician scientists. This grant is designed for people trained primarily as clinicians who want to maintain clinical practice and conduct cancer research.
Institutional Research Grants	2026-06-01	$120,000/yr for 4 years	American Cancer Society (ACS)	Mid-Career	Click for details Institutional Research Grants are awarded to institutions as block grants, providing seed money for newly independent investigators to initiate cancer research projects. The intent is to support these junior faculty in initiating cancer research projects so they can obtain preliminary results that will enable them to compete successfully for national research grants.
RFA: Extramural Discovery Science Accelerator Award	2026-06-01	$75,000	American Cancer Society (ACS)	Early Career / Mid-Career	Click for details The intent of the Extramural Discovery Science (EDS) Accelerator Award is to support the commercialization of an ongoing cancer research project and to validate and de-risk technologies. Proposals should address key experiment(s) required to move findings toward commercialization that do not easily fit into traditional grant funding mechanisms. This mechanism is not designed to initiate new projects or develop new directions for an ongoing project. The proposal should be commercially driven with the PI having a plan to license the technology, either to an established company or a start-up if the experiment(s) are successful. Examples of research that align with the focus of this funding initiative include but are not limited to: Dosing, toxicity and/or efficacy testing Testing of biopsies or other patient samples to correlate clinical outcome Technologies for healthcare delivery Accelerator awardees will become part of an entrepreneurial collaborative learning community focused on technology commercialization. Grantees will have access to both educational programming developed by the ACS BrightEdge team and the team itself.
TheoryLab Collaborative (TLC) Grant	2026-06-01	$61,200	American Cancer Society (ACS)	Early Career / Mid-Career	Click for details The TheoryLab Collaborative (TLC) Grant mechanism is intended to provide pilot grant support for collaborative cancer research projects between two members of the American Cancer Society (ACS) research ecosystem, including current and former grantees and ACS intramural scientists. Our goal is to invest in our ACS scientific community to enable the formation of new and interdisciplinary collaborations and test out a new idea or concept. The proposed project can focus anywhere along the cancer research continuum but must be collaborative and interdisciplinary. We highly encourage investigators to form new collaborations; current or former collaborators may apply for a TLC Grant, but their proposed project must be different from their previous collaborative project(s). In addition, co-PI's may be at the same institution but must be in a different department/discipline. Grantees will give a virtual presentation at an informal, virtual retreat ~6 months after the grant ends, detailing the outcomes, challenges, and future work of the project.
ACS Professor Award	2026-06-01	$80,000/yr for 5 years	American Cancer Society (ACS)	Mid-Career	Click for details ACS Professor awards are primarily honorific awards for individuals who have made seminal contributions in cancer research. Applicants must have obtained the rank of full professor, and, at the time of application, applicants must have been a full professor for 5 or more years but no more than 20 years. It is expected that applicants have made and will likely continue to make, impactful contributions to change the direction of cancer research. These notable cancer research achievements could have been fundamental, preclinical, clinical, psychosocial, behavioral, health policy and/or epidemiologic in focus. Commitment and success in scientific mentoring and leadership as well as community engagement are also carefully considered.
Mission Boost Grants (MBG)	2026-06-01	$135,000/yr up to 2 years	American Cancer Society (ACS)	Early Career / Mid-Career	Click for details Mission Boost Grants (MBG) are designed to support research projects that specifically focus on translation to human testing. MBGs are opportunities for independent investigators at all levels to apply for additional, or "boost," resources for innovative, clinical-enabling projects. MBGs offer 2 stages of funding: Stage I requires the investigator to develop outcome-specific, unequivocal milestones that reduce the risks of studying a new drug, device, or procedure in patients. Stage II supports testing in cancer patients.
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01-Clinical Trial Not Allowed)	2026-06-05	$499,000/yr for 5 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The purpose of this Notice of Funding Opportunity (NOFO) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.
NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)	2026-06-05	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details This notice of funding opportunity (NOFO) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science.
Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)	2026-06-05	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details This Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic contributors of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)	2026-06-05	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.
Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)	2026-06-05	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R01 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. Specific research interests of participating NIH ICs are detailed within.
Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01-Clinical Trials Optional)	2026-06-05	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details This initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations who experience health disparities in the United States (U.S.).
Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)	2026-06-05	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, and Alaskan Native populations.
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)	2026-06-05	$250,000/yr for 5 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)	2026-06-10	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This NOFO supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer’s, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. Research projects that do not involve the use of PLCO biospecimens will not be supported under this NOFO.
Independent Scientist Award (Parent K02-Independent Clinical Trial Not Allowed)	2026-06-12	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.
NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)	2026-06-12	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career	Click for details The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.
Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)	2026-06-12	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.
Mentored Research Scientist Development Award (Parent K01-Independent Clinical Trial Not Allowed)	2026-06-12	varies to reflect the needs of the project	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs use the K01 to support career development in specific fields.
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)	2026-06-16	$275,000 over 2 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA.
NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)	2026-06-16	$275,000 over 2 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)	2026-06-16	$275,000 over 2 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)	2026-06-16	$275,000 over 2 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer.
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)	2026-06-16	$275,000 over 2 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote the dissemination and implementation of evidence-based interventions among relevant communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters remain relevant.
Technology Development Research for Establishing Feasibility and Proof of Concept (R21-Clinical Trial Not Allowed)	2026-06-16	$275,000 over 2 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details This Notice of Funding Opportunity (NOFO)supports exploratory research leading to proof of concept for the development of new technologies relevant to the NIGMS mission. Projects should entail a high degree of risk and/or novelty, and have a high future potential impact in biomedical research. Outcomes or products of the proposed project, which should significantly advance the current state of the art, may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention for use as research tools.
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)	2026-06-25	$375,000 over 3 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions.
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)	2026-06-25	$375,000 over 3 years	National Institutes of Health (NIH)	Early Career / Mid-Career	Click for details The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions.